Bio Blast Pharma Revenue, Profits - ORPN Quarterly Income Statement

Add to My Stocks
$1.28 $0.03 (2.4%) ORPN stock closing price Sep 18, 2018 (Closing)

Financial analysis of Bio Blast Pharma involves more than just checking the Bio Blast Pharma stock price, by looking at the financial statements of the company in detail. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the ORPN stock is bound to reflect the impact of the QOQ decline of 0. Revenue for year 2017 Q4 is $- and has decreased from $- quarter on quarter as is evident when you compare the latest figures in the latest Bio Blast Pharma profit and loss statement with those of the prior corresponding period. Also see Bio Blast Pharma assets and Bio Blast Pharma free cash flow for a complete valuation of ORPN stock.

View and download details of revenue and profits for Bio Blast Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Bio Blast Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)---------
Bio Blast Pharma Gross Profit
Research & Development Expense---1.09M1.81M3.29M1.93M1.85M1.89M
Selling General & Admin Expense---1.54M1.29M1.28M1.78M2.63M2.96M
Income Before Depreciation Depletion Amortization-0.59M-1.07M-1.65M-2.64M-3.08M-4.57M-3.72M-4.49M-4.85M
Depreciation Depletion Amortization---------
Non Operating Income---------
Interest Expense---------
Bio Blast Pharma Pretax Income
Provision for Income Taxes-0.01M-0.01M-----0.02M--
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-0.57M-1.07M-1.63M-2.67M-3.07M-4.67M-3.69M4.59M-4.83M
Extraordinary Items & Discontinued Operations---------
Bio Blast Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS3.41M3.34M3.29M3.28M3.28M3.28M3.28M2.89M2.85M
Average Shares used to compute Basic EPS3.41M3.34M3.29M3.28M3.28M3.28M3.28M2.89M2.85M
Income Before Nonrecurring Items-0.57M-1.07M-1.63M-2.67M-3.07M-4.67M-3.69M4.59M-4.83M
Income from Nonrecurring Items---------
Bio Blast Pharma Earnings Per Share Basic Net
Bio Blast Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.17-0.32-0.50-0.80-0.95-1.40-1.101.60-1.70
Preferred Dividends Acc Pd---------
Dividends Common0.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our Galmed Pharma financial analysis

It is very helpful to read a report on Bio Blast Pharma stock analysis. An investor must check the following items in an income statement:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that ORPN stock has a topline or revenue of $- for 2017 Q4 as per this Bio Blast Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: Most businesses like Bio Blast Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called the profit and loss statement. Apart from the ORPN income statement, one can check the Bio Blast Pharma historical stock prices to check how the price has moved with time.

Bio Blast Pharma Income Statement - Key Financial Ratios